Page 16 - Trials Network News Today

A third person was reportedly cured of HIV after receiving a bone marrow using umbilical cord blood stem cell treatment for leukemia.

An unknown American lady was identified with HIV 10 years ago. She confronted anti-retroviral medications, just like hundreds and hundreds of patients who show symptoms in the United States annually, to protect the infection from decimating her inflammatory response. However, that is no longer the situation today.

Ten years ago, an unnamed American woman was diagnosed with HIV. Like the tens of thousands of people who test positive in the US each year, she faced a lifetime of anti-retroviral therapies to keep the virus from obliterating her immune system.

Amita Gupta, M.D., M.H.S., an expert in the global treatment, prevention and control of diseases such as acquired immunodeficiency syndrome (AIDS) and tuberculosis (TB), has been named as the seventh director of Johns Hopkins Medicine’s Division of I

Zacchaeus Anywaine and co-workers study safety and immunogenicity of an Ebola vaccine among children and adolescents across four African countries.

Carlos Del Rio is Rollins Professor and chair of the Hubert Department of Global Health. He also co-directs the Emory Center for AIDS Research and leads the Emory AIDS International Training and Research Program (AITRP).

Yesterday the U.S. Food and Drug Administration announced its first approval of a long-acting HIV prevention medication. Developed by ViiV Healthcare, the medicine is long-acting cabotegravir injected...

The CAB-LA injection is the first of its kind in HIV prevention interventions and only needs to be taken every eight weeks

Yesterday the U.S. Food and Drug Administration announced its first approval of a long-acting HIV prevention medication. Developed by ViiV Healthcare, the medicine is long-acting cabotegravir injected once every two months.

Approval marks pivotal expansion of HIV prevention options in the United States. Yesterday the U.S. Food and Drug Administration announced its first